Small cell lung cancer with liver metastases: from underlying mechanisms to treatment strategies.

IF 7.7 2区医学 Q1 ONCOLOGY

Cancer and Metastasis Reviews Pub Date : 2024-11-25 DOI:10.1007/s10555-024-10220-8

Linjie Fan, Yiwen Lin, Yunjie Fu, Jie Wang

{"title":"Small cell lung cancer with liver metastases: from underlying mechanisms to treatment strategies.","authors":"Linjie Fan, Yiwen Lin, Yunjie Fu, Jie Wang","doi":"10.1007/s10555-024-10220-8","DOIUrl":null,"url":null,"abstract":"<p><p>Small cell lung cancer (SCLC) represents an aggressive neuroendocrine (NE) tumor within the pulmonary region, characterized by very poor prognoses. Druggable targets for SCLC remain limited, thereby constraining treatment options available to patients. Immuno-chemotherapy has emerged as a pivotal therapeutic strategy for extensive-stage SCLC (ES-SCLC), yet it fails to confer significant efficacy in cases involving liver metastases (LMs) originating from SCLC. Therefore, our attention is directed towards the challenging subset of SCLC patients with LMs. Disease progression of LM-SCLC patients is affected by various factors in the tumor microenvironment (TME), including immune cells, blood vessels, inflammatory mediators, metabolites, and NE substances. Beyond standard immuno-chemotherapy, ongoing efforts to manage LMs in SCLC encompass anti-angiogenic therapy, radiotherapy, microwave ablation (MWA) / radiofrequency ablation (RFA), trans-arterial chemoembolization (TACE), and systemic therapies in conjunction with local interventions. Prospective experimental and clinical investigations into SCLC should prioritize precise and individualized approaches to enhance the prognosis across distinct patient cohorts.</p>","PeriodicalId":9489,"journal":{"name":"Cancer and Metastasis Reviews","volume":"44 1","pages":"5"},"PeriodicalIF":7.7000,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer and Metastasis Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10555-024-10220-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Small cell lung cancer (SCLC) represents an aggressive neuroendocrine (NE) tumor within the pulmonary region, characterized by very poor prognoses. Druggable targets for SCLC remain limited, thereby constraining treatment options available to patients. Immuno-chemotherapy has emerged as a pivotal therapeutic strategy for extensive-stage SCLC (ES-SCLC), yet it fails to confer significant efficacy in cases involving liver metastases (LMs) originating from SCLC. Therefore, our attention is directed towards the challenging subset of SCLC patients with LMs. Disease progression of LM-SCLC patients is affected by various factors in the tumor microenvironment (TME), including immune cells, blood vessels, inflammatory mediators, metabolites, and NE substances. Beyond standard immuno-chemotherapy, ongoing efforts to manage LMs in SCLC encompass anti-angiogenic therapy, radiotherapy, microwave ablation (MWA) / radiofrequency ablation (RFA), trans-arterial chemoembolization (TACE), and systemic therapies in conjunction with local interventions. Prospective experimental and clinical investigations into SCLC should prioritize precise and individualized approaches to enhance the prognosis across distinct patient cohorts.

查看原文本刊更多论文

肝转移的小细胞肺癌：从基本机制到治疗策略。

小细胞肺癌（SCLC）是肺部一种侵袭性神经内分泌（NE）肿瘤，预后极差。小细胞肺癌的可治疗靶点仍然有限，从而限制了患者的治疗选择。免疫化疗已成为广泛期SCLC（ES-SCLC）的关键治疗策略，但对于SCLC肝转移（LMs）病例却没有显著疗效。因此，我们将目光投向了具有 LMs 的 SCLC 患者这一具有挑战性的亚群。LM-SCLC患者的疾病进展受到肿瘤微环境（TME）中各种因素的影响，包括免疫细胞、血管、炎症介质、代谢产物和NE物质。除了标准的免疫化疗外，目前治疗SCLC LMs的方法还包括抗血管生成治疗、放射治疗、微波消融（MWA）/射频消融（RFA）、经动脉化疗栓塞（TACE）以及与局部干预相结合的全身治疗。针对 SCLC 的前瞻性实验和临床研究应优先考虑精确和个体化的方法，以改善不同患者群的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer and Metastasis Reviews 医学-肿瘤学

CiteScore

17.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Contemporary biomedical research is on the threshold of an era in which physiological and pathological processes can be analyzed in increasingly precise and mechanistic terms.The transformation of biology from a largely descriptive, phenomenological discipline to one in which the regulatory principles can be understood and manipulated with predictability brings a new dimension to the study of cancer and the search for effective therapeutic modalities for this disease. Cancer and Metastasis Reviews provides a forum for critical review and discussion of these challenging developments. A major function of the journal is to review some of the more important and interesting recent developments in the biology and treatment of malignant disease, as well as to highlight new and promising directions, be they technological or conceptual. Contributors are encouraged to review their personal work and be speculative.